0KBS.LSE Recordati

Healthcare Commercial Services & Supplies London Exchange
- EUR
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
0.03%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2022.

Is 0KBS.LSE undervalued?

Graham number

The Graham number of Recordati cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Recordati fundamental analysis

No fundamental analysis for Recordati yet.

Recordati stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Recordati

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular m…

Full company profile